Nautilus Biotechnology Stock Analysis
NAUT Stock | USD 2.30 0.06 2.68% |
Nautilus Biotechnology is undervalued with Real Value of 2.95 and Target Price of 5.0. The main objective of Nautilus Biotechnology stock analysis is to determine its intrinsic value, which is an estimate of what Nautilus Biotechnology is worth, separate from its market price. There are two main types of Nautilus Biotechnology's stock analysis: fundamental analysis and technical analysis.
The Nautilus Biotechnology stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Nautilus Biotechnology is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Nautilus Stock trading window is adjusted to America/New York timezone.
Nautilus |
Nautilus Stock Analysis Notes
About 33.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.29. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Nautilus Biotechnology recorded a loss per share of 0.56. The entity had not issued any dividends in recent years. Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company was founded in 2016 and is headquartered in Seattle, Washington. Nautilus Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people. To find out more about Nautilus Biotechnology contact Sujal Patel at 206 333 2001 or learn more at https://www.nautilus.bio.Nautilus Biotechnology Investment Alerts
Nautilus Biotechnology generated a negative expected return over the last 90 days | |
Nautilus Biotechnology has high historical volatility and very poor performance | |
Net Loss for the year was (63.67 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Nautilus Biotechnology currently holds about 299.34 M in cash with (51.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Nautilus Biotechnology has a poor financial position based on the latest SEC disclosures | |
Roughly 33.0% of the company outstanding shares are owned by corporate insiders | |
Latest headline from finance.yahoo.com: 3 US Penny Stocks With Market Caps Up To 400M |
Nautilus Biotechnology Upcoming and Recent Events
22nd of February 2024 Upcoming Quarterly Report | View | |
7th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
22nd of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Nautilus Largest EPS Surprises
Earnings surprises can significantly impact Nautilus Biotechnology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-07-30 | 2024-06-30 | -0.16 | -0.14 | 0.02 | 12 | ||
2023-08-02 | 2023-06-30 | -0.15 | -0.13 | 0.02 | 13 | ||
2021-11-02 | 2021-09-30 | -0.1 | -0.12 | -0.02 | 20 |
Nautilus Biotechnology Environmental, Social, and Governance (ESG) Scores
Nautilus Biotechnology's ESG score is a quantitative measure that evaluates Nautilus Biotechnology's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Nautilus Biotechnology's operations that may have significant financial implications and affect Nautilus Biotechnology's stock price as well as guide investors towards more socially responsible investments.
Nautilus Biotechnology Thematic Classifications
In addition to having Nautilus Biotechnology stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Measuring and Control EquipmentUSA Equities from Measuring and Control Equipment industry as classified by Fama & French |
Nautilus Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Dimensional Fund Advisors, Inc. | 2024-09-30 | 692 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 643.1 K | Clarius Group, Llc | 2024-09-30 | 636.5 K | Botty Investors Llc | 2024-09-30 | 614.3 K | Northern Trust Corp | 2024-09-30 | 507.5 K | Alyeska Investment Group, L.p. | 2024-09-30 | 441 K | Sentinel Trust Co Lba | 2024-09-30 | 315 K | Wexford Capital Lp | 2024-06-30 | 208.3 K | Hillman Co | 2024-09-30 | 200 K | Perceptive Advisors Llc | 2024-09-30 | 12.6 M | Cercano Management Llc | 2024-09-30 | 7.2 M |
Nautilus Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 288.8 M.Nautilus Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.21) | (0.20) | |
Return On Capital Employed | (0.26) | (0.27) | |
Return On Assets | (0.21) | (0.20) | |
Return On Equity | (0.24) | (0.23) |
Management Efficiency
Nautilus Biotechnology has return on total asset (ROA) of (0.1762) % which means that it has lost $0.1762 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2804) %, meaning that it created substantial loss on money invested by shareholders. Nautilus Biotechnology's management efficiency ratios could be used to measure how well Nautilus Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.2 in 2024. Return On Capital Employed is likely to drop to -0.27 in 2024. Total Current Liabilities is likely to drop to about 4.6 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 239 M in 2024Last Reported | Projected for Next Year | ||
Book Value Per Share | 2.12 | 1.49 | |
Tangible Book Value Per Share | 2.12 | 1.49 | |
Enterprise Value Over EBITDA | (5.23) | (5.49) | |
Price Book Value Ratio | 1.41 | 2.12 | |
Enterprise Value Multiple | (5.23) | (5.49) | |
Price Fair Value | 1.41 | 2.12 |
Nautilus Biotechnology benefits from a management team that prioritizes both innovation and efficiency. We analyze these priorities to gauge the stock's future performance.
Beta 1.036 | Return On Assets (0.18) | Return On Equity (0.28) |
Technical Drivers
As of the 28th of November, Nautilus Biotechnology secures the Risk Adjusted Performance of (0.02), standard deviation of 3.89, and Mean Deviation of 3.05. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nautilus Biotechnology, as well as the relationship between them.Nautilus Biotechnology Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Nautilus Biotechnology middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Nautilus Biotechnology. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Nautilus Biotechnology Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nautilus Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nautilus Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Nautilus Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Nautilus Biotechnology Outstanding Bonds
Nautilus Biotechnology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Nautilus Biotechnology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Nautilus bonds can be classified according to their maturity, which is the date when Nautilus Biotechnology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
NWG 16 29 SEP 26 Corp BondUS63906YAD04 | View | |
NWG 5903249 22 MAR 25 Corp BondUS63906YAF51 | View | |
NWG 3479 22 MAR 25 Corp BondUS63906YAG35 | View | |
NWG 5516 30 SEP 28 Corp BondUS639057AF59 | View | |
NWG 46 Corp BondUS639057AD02 | View | |
NATWEST GROUP PLC Corp BondUS639057AC29 | View | |
NWG 5847 02 MAR 27 Corp BondUS639057AJ71 | View | |
NWG 6016 02 MAR 34 Corp BondUS639057AH16 | View |
Nautilus Biotechnology Predictive Daily Indicators
Nautilus Biotechnology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Nautilus Biotechnology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Nautilus Biotechnology Corporate Filings
F3 | 14th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
8K | 29th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 25th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 18th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 17th of September 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 30th of July 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 17th of June 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 13th of June 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Nautilus Biotechnology Forecast Models
Nautilus Biotechnology's time-series forecasting models are one of many Nautilus Biotechnology's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Nautilus Biotechnology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Nautilus Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Nautilus Biotechnology prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Nautilus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Nautilus Biotechnology. By using and applying Nautilus Stock analysis, traders can create a robust methodology for identifying Nautilus entry and exit points for their positions.
Last Reported | Projected for Next Year |
Current Nautilus Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Nautilus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Nautilus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
5.0 | Buy | 5 | Odds |
Most Nautilus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Nautilus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Nautilus Biotechnology, talking to its executives and customers, or listening to Nautilus conference calls.
Nautilus Stock Analysis Indicators
Nautilus Biotechnology stock analysis indicators help investors evaluate how Nautilus Biotechnology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Nautilus Biotechnology shares will generate the highest return on investment. By understating and applying Nautilus Biotechnology stock analysis, traders can identify Nautilus Biotechnology position entry and exit signals to maximize returns.
Begin Period Cash Flow | 115.5 M | |
Common Stock Shares Outstanding | 124.9 M | |
Total Stockholder Equity | 265.4 M | |
Property Plant And Equipment Net | 36.9 M | |
Cash And Short Term Investments | 173.4 M | |
Cash | 19.4 M | |
Accounts Payable | 1.6 M | |
Net Debt | 15.2 M | |
50 Day M A | 2.6801 | |
Total Current Liabilities | 9.1 M | |
Other Operating Expenses | 76.2 M | |
Non Current Assets Total | 128.7 M | |
Non Currrent Assets Other | 1.2 M | |
Stock Based Compensation | 12.1 M |
Additional Tools for Nautilus Stock Analysis
When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.